DSS

DSS, Inc. 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025, for DSS, Inc. (NYSE American: DSS), a diversified holding company operating four primary segments: Product Packaging (Premier Packaging), Biotechnology (Impact BioMedical), Commercial Lending (American Pacific Financial), and Securities and Investment Management (including REITs and broker-dealer activities). The company is classified as a Non-Accelerated Filer and a Smaller Reporting Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 9% year-over-year, driven by a 12% increase in Printed Products revenue and a 39% surge in Commission revenue from the Securities segment. Conversely, Rental income dropped 31% due to vacancy at the Pittsburgh facility, and Commercial Lending revenue fell 80% as loans moved to non-accrual status.
• Reduced Losses: The net loss improved significantly from $53.7 million in 2024 to $27.5 million in 2025. This improvement was largely due to the absence of a $25.1 million goodwill impairment charge recorded in 2024 and a reduction in real estate impairment charges.
• Asset Dispositions: The company sold several real estate assets in 2025, including facilities in Plano, TX, and Winter Haven, FL. These sales generated approximately $15.7 million in cash but resulted in a net loss on sale of assets totaling $9.6 million.
• Debt Restructuring: Total debt decreased as proceeds from asset sales were used to pay down obligations. However, a significant $37.0 million loan related to the AMRE LifeCare portfolio is currently in default.

Guidance, Outlook, and Risks

Management Commentary & Strategy: Management is focused on operational efficiency, targeting a 15-20% cost reduction in the upcoming fiscal year. Strategic priorities include expanding high-margin packaging markets (medical, food & beverage), advancing biotechnology R&D (specifically the "LineBacker" and "Laetose" platforms), and monetizing the Impact BioMedical subsidiary through its recent IPO and potential reverse merger with Dr. Ashleys Limited.

Going Concern: The independent auditor has issued a "Going Concern" opinion, citing substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows from operations. Management plans to address this through asset sales, equity issuances, and debt financing.

Key Risks:

• Debt Default: The $37.0 million LifeCare loan is in default and due immediately. Failure to negotiate an extension or settlement could lead to foreclosure.
• Customer Concentration: One customer accounted for 29% of consolidated revenue in 2025.
• Intangible Asset Impairment: Approximately $17.0 million in intangible assets (primarily related to Impact BioMedical) are at risk of impairment if licensing efforts fail.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including insufficient segregation of duties and lack of systematic reconciliation procedures.

Investor Verification Checklist

• Debt Status: Verify the current status of the $37.0 million AMRE LifeCare loan default and any agreements reached with Pinnacle Bank.
• Impact BioMedical Merger: Confirm the regulatory approval status and closing timeline for the reverse merger with Dr. Ashleys Limited.
• Intangible Valuation: Review the assumptions used to value the $17.0 million in intangible assets, particularly given the history of impairments in this sector.
• Internal Control Remediation: Assess the progress of remediation efforts for the identified material weaknesses in internal controls.
• Liquidity Runway: Evaluate the sufficiency of the $6.2 million cash balance against the $36.1 million total debt and ongoing operating cash burn.